GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
GO:003052228 | Thyroid | PTC | intracellular receptor signaling pathway | 126/5968 | 265/18723 | 6.31e-08 | 1.31e-06 | 126 |
GO:0071383112 | Thyroid | PTC | cellular response to steroid hormone stimulus | 98/5968 | 204/18723 | 9.83e-07 | 1.47e-05 | 98 |
GO:004340124 | Thyroid | PTC | steroid hormone mediated signaling pathway | 69/5968 | 136/18723 | 3.57e-06 | 4.58e-05 | 69 |
GO:000975519 | Thyroid | PTC | hormone-mediated signaling pathway | 80/5968 | 190/18723 | 1.84e-03 | 9.91e-03 | 80 |
GO:0048545210 | Thyroid | ATC | response to steroid hormone | 168/6293 | 339/18723 | 7.21e-10 | 1.88e-08 | 168 |
GO:0030522112 | Thyroid | ATC | intracellular receptor signaling pathway | 134/6293 | 265/18723 | 7.58e-09 | 1.63e-07 | 134 |
GO:007138328 | Thyroid | ATC | cellular response to steroid hormone stimulus | 103/6293 | 204/18723 | 4.32e-07 | 6.30e-06 | 103 |
GO:0043401111 | Thyroid | ATC | steroid hormone mediated signaling pathway | 71/6293 | 136/18723 | 5.72e-06 | 6.07e-05 | 71 |
GO:0009755110 | Thyroid | ATC | hormone-mediated signaling pathway | 83/6293 | 190/18723 | 2.34e-03 | 1.09e-02 | 83 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RXRG | SNV | Missense_Mutation | novel | c.212N>A | p.Arg71Gln | p.R71Q | P48443 | protein_coding | tolerated_low_confidence(0.28) | benign(0.427) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RXRG | SNV | Missense_Mutation | rs748834240 | c.1265G>A | p.Arg422His | p.R422H | P48443 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RXRG | SNV | Missense_Mutation | | c.136N>G | p.Thr46Ala | p.T46A | P48443 | protein_coding | tolerated_low_confidence(0.16) | benign(0.015) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RXRG | SNV | Missense_Mutation | | c.241T>A | p.Ser81Thr | p.S81T | P48443 | protein_coding | tolerated(0.08) | benign(0.224) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RXRG | SNV | Missense_Mutation | | c.92N>T | p.Ala31Val | p.A31V | P48443 | protein_coding | tolerated_low_confidence(0.35) | benign(0.042) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
RXRG | SNV | Missense_Mutation | novel | c.988N>A | p.Gly330Ser | p.G330S | P48443 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RXRG | SNV | Missense_Mutation | novel | c.569N>A | p.Arg190His | p.R190H | P48443 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RXRG | SNV | Missense_Mutation | novel | c.118N>T | p.Asp40Tyr | p.D40Y | P48443 | protein_coding | tolerated_low_confidence(0.18) | possibly_damaging(0.678) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
RXRG | SNV | Missense_Mutation | novel | c.1343T>C | p.Ile448Thr | p.I448T | P48443 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RXRG | SNV | Missense_Mutation | novel | c.1142C>T | p.Ala381Val | p.A381V | P48443 | protein_coding | tolerated(0.47) | probably_damaging(0.996) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL705 | ALITRETINOIN | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | NRX-4204 | | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL1023 | BEXAROTENE | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | ADAPALENE | ADAPALENE | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650520 | BEXAROTENE | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | 9cUAB-30 | | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | TRETINOIN | TRETINOIN | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | ALITRETIONINE | | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL75133 | IRX-4204 | |
6258 | RXRG | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL1131 | ACITRETIN | |